Evaluation of the frequency of BCL2 and P53 and angiogenesis in endometrial cancer and its relationship with clinicopathological characteristics

Document Type : Original Article

Authors

1 Associate professor, Department of Obstetrics and Gynecology, Women's Health Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Assistant Professor, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Associate professor, Department of Radiotherapy and Oncology, Solid Tumor Treatment Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Associated Professor, Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Resident of Obstetrics and Gynecology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction: P53 is mutated in more than 50% of solid tumors and has been changed in 30-40% of endometrial cancer which is the most common malignancy of the genital tract of women and this change is associated with papillary serous cell type and advanced stage and poor prognosis. In addition, the overexpression of BCL2 and tumor angiogenesis is important in the prognosis of patient. Therefore, this study was performed with aim to evaluate the expression of BCL2 and P53 and angiogenesis in endometrial cancer and its relationship with clinicopathological characteristics and the factors affecting the prognosis of disease.
Methods: In this retrospective longitudinal study which was performed during 2005-2014, 30 files of patients with endometrial cancer in three different hospitals (Imam Reza, Ghaem, Omid) were collected. The pathology samples were immunohistochemical staining in terms of Bcl2 and P53 markers and angiogenesis and the association of these markers with factors affecting the prognosis and recurrence of disease were investigated. Log rank, t-test and Chi-square tests were used to analyze the data and PResults: P53 expression was positive in 9 cases of 10 patients (90%) with non-endometrial cancer and all patients (100%) were negative in terms of Bcl2 and angiogenesis was severe in 8 cases of 10 patients (80%) with non-endometrial cancer and in 6 cases of 20 patients (30%) with endometrial cancer. There was significant relation between tumor histology and tumor grade and stage of the disease and survival (P = 0.002).
Conclusion: Since there is relationship between genetic markers with stage and grade of disease and also survival of the patients, it is better that the related block be evaluated in terms of these markers at the time of pathological diagnosis of endometrial cancer.

Keywords

References

  1. Dobrzycka B, Terlikowski SJ, Mazurek A et al. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer. 2010;127:612–621.
  2. Dobrzycka B, Terlikowski SJ, Mazurek A et al. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma. Folia Histochem Cytobiol. 2009;47:65–68.
  3. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS. 2009;117:693–707.
  4. Porichi O, Nikolaidou ME, Apostolaki A et al. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry. Anticancer Res. 2009;29:3977–3982.
  5. Dobrzycka B1, Terlikowski SJ, Garbowicz M, Niklinski J, Chyczewski L, Kulikowski M. The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer. Folia Histochem Cytobiol. 2011;49(4):631-5.
  6. Robbe EJ1, van Kuijk SM, de Boed EM, Smits LJ, van der Wurff AA, Kruitwagen RF, Pijnenborg JM. Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples. Int J Gynecol Cancer. 2012 Sep;22(7):1264-72.
  7. Doll A, Abal M, Rigau M et al. Novel molecular profiles of endometrial cancer - new light through old windows. J Steroid Biochem Mol Biol. 2008;108:221–229.
  8. Pilka R1, Mícková I, Lubuský M, Dusková M, Rícánková M, Kudela M. [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer]. Ceska Gynekol. 2008 Jul;73(4):222-7.
  9. Markova I1, Duskova M, Lubusky M, Kudela M, Zapletalová J, Procházka M, Pilka R. Selected immunohistochemical prognostic factors in endometrial cancer. Int J Gynecol Cancer. 2010 May;20(4):576-82.
  10. Pilka R1, Marková I, Dusková M, Zapletalová J, Tozzi M, Kudela M. Immunohistochemical markers expression in hysteroscopy and hysterectomy specimens from endometrialcancer patients: comparison. Ceska Gynekol. 2010 May;75(3):165-70.
  11. González-Rodilla I, Verna V, Muñoz AB, Estévez J, Boix M, Schneider J. Expression of the apoptosis-related genes Bcl-2 and p53 in clinical samples from endometrialcarcinoma patients. Anticancer Res. 2011 Dec;31(12):4191-3.
  12. Kudela M, Pilka R, Lubuský M, Hejtmánek P, Dzubák P, Brychtová S. Prognostic importance of selected molecular genetic immunohistochemical markers and DNA ploidy in endometrial cancer. Ceska Gynekol. 2011 Jun;76(3):194-9.
  13. Erdem O, Erdem M, Dursun A, Akyol G, Erdem A. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables. Int J Gynecol Pathol. 2003 Jul;22(3):254-60.
  14. Busmanis I1, Ho TH, Tan SB, Khoo KS. p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium. Ann Acad Med Singapore. 2005 Aug;34(7):421-5.
  15. Jongen VH, Briët JM, de Jong RA, et al. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer. 2009;19:670–676.
  16. Kalogiannidis I, Bobos M, Papanikolaou A, et al. Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes. Eur J Gynaecol Oncol. 2008;29:19–25.
  17. Ohkouchi T1, Sakuragi N, Watari H, Nomura E, Todo Y, Yamada H, et al. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol. 2002 Aug;187(2):353-9.
  18. Appel ML, Edelweiss MI, Fleck J et al. P53 and BCL-2 as prognostic markers in endometrial carcinoma. Pathol Oncol Res. 2008;14:23–30.
  19. Stoenescu TM, Ivan LD, Stoenescu N, Azoicăi D. Assessment tumor markers by immunohistochemistry (Ki67, p53 and Bcl-2) on a cohort of patients with cervical cancer in various stages of evolution. Rev Med Chir Soc Med Nat Iasi. 2011 Apr-Jun;115(2):485-92.
  20. Laas E1, Ballester M2, Cortez A3, Gonin J3, Daraï E4, Graesslin O5. Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer. Gynecol Oncol. 2014 May;133(2):205-10.
  21. Apostolou G1, Apostolou N, Biteli M, Kavantzas N, Patsouris E, Athanassiadou P. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology. Diagn Cytopathol. 2014 Feb;42(2):134-42.
  22. Henríquez-Hernández LA, Lloret M, Pinar B, Bordón E, Rey A, Lubrano A, et al. BCL-2, in combination with MVP and IGF-1R expression, improves prediction of clinical outcome in complete response cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol. 2011 Sep;122(3):585-9.
  23. Sorbe B, Risberg B. Prognostic importance of the nuclear proteins p53 and Rb in conjunction with DNA, nuclear morphometry and grading in endometrial carcinoma. Int J Gynecol Cancer. 1997; 7(1): 34-41.
  24. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI; Tumor and Angiogenesis Research Group. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer. 2002 Sep 1;95(5):1055-63.
  25. Ohkouchi T1, Sakuragi N, Watari H, Nomura E, Todo Y, Yamada H, et al. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol. 2002;187(2):353-9.

Files

Share

How to cite

Statistics